

NOTICE AND AGENDA
ANNUAL GENERAL MEETING 2018 CURETIS N.V.

The Management Board and the Supervisory Board of Curetis N.V. hereby invite you to attend the annual general meeting to be held at the Steigenberger Hotel, Stationsplein Zuid-West 951, 1117 CE Schiphol Airport, the Netherlands, on Thursday 21 June 2018. The meeting shall commence at 13.00 hours CEST; registration starts at 12.30 hours CEST.

The items on the agenda are:

1. opening of the meeting;
2. the presentation of the management report 2017 (discussion item);
3. the implementation of the new Dutch Corporate Governance Code within the Company and an amendment of the Supervisory Board Profile (discussion item);
4. the explanation of the Management Board remuneration policy (discussion item);
5. the adoption of the annual accounts 2017 and the allocation of the result (voting item);
6. the explanation on the company's reserves and dividend policy (discussion item);
7. the discharge of the Managing Directors for their management during the financial year 2017 (voting item);
8. the discharge of the Supervisory Directors for their supervision during the financial year 2017 (voting item);
9. the appointment of Managing Directors (voting item);
10. the authorisation of Supervisory Board to grant stock options to Managing Directors (voting item);
11. the amendment of the Management Board remuneration policy (voting item);
12. the appointment of Supervisory Directors (voting item);
13. the approval of granting stock options to Supervisory Directors (voting item);
14. the appointment of the auditor for the financial year 2018 (voting item);
15. the extension of the designation of the Management Board as the company body authorised to issue new shares and rights to subscribe for shares (voting item);
16. the extension of the designation of the Management Board as the company body authorised to limit or exclude pre-emption rights on newly issued shares or rights to subscribe for shares (voting item);
17. the extension of the authorisation of the Management Board to repurchase shares (voting item);
18. the designation of the Management Board as the company body authorised to issue new shares and/or grant rights to subscribe for shares in relation to strategic capital raising(s) (voting item);
19. the designation of the Management Board as the company body authorised to limit or exclude pre-emption rights on newly issued shares or rights to subscribe for shares in relation to strategic capital raising(s) (voting item);
20. the amendment of the articles of association of Curetis N.V. (technical aspect concerning the new Dutch Corporate Governance Code) (voting item);
21. questions and close of meeting.

At the date of this notice, the issued share capital of Curetis N.V. comprises of 16,392,577 ordinary shares with a nominal value of EUR 0.01 each. Each share confers the right to cast one vote.

As of the date hereof, this notice, the agenda, the explanatory notes to the agenda, the annual accounts 2017, the management report 2017, the Supervisory Board profile, the draft Management Board remuneration policy and the draft deed of amendment of the articles of association are available for inspection at www.curetis.com. Furthermore, these items can be obtained free of charge:

- (a) at the offices of ABN AMRO Bank N.V. at Gustav Mahlerlaan 10, 1082 PP Amsterdam, the Netherlands, or by e-mail via corporate.broking@nl.abnamro.com; and
- (b) at the offices of Curetis N.V. at Max-Eyth-Straße 42, 71088 Holzgerlingen, Germany, or by e-mail via ir@curetis.com.

Record date

The persons who (i) on 24 May 2018 (after processing the purchases and orders on that date) (the "**Record Date**") are registered in the administration of the Intermediaries of Euroclear Nederland as persons entitled to shares in the share capital of Curetis N.V., and (ii) have duly registered for participation in the meeting, shall have the right to attend and vote at or prior to the meeting, irrespective of who are entitled to the shares at the time of the meeting.

Registration for attending the meeting

Shareholders who wish to attend the meeting either in person or by proxy must notify ABN AMRO Bank N.V. ("**ABN AMRO**"), via their bank or broker (the "**Intermediaries**"), that they wish to attend the meeting. Shareholders may also register for the meeting via www.abnamro.com/evoting. Registration requests via Intermediaries or the website of ABN AMRO may be submitted as from Friday 25 May 2018 and not later than on Thursday 14 June 2018 17.30h CEST.

No later than on Friday 15 June 2018 13.00h CEST, the Intermediaries must provide ABN AMRO with a statement mentioning (i) the number of shares held by each of the shareholders on the Record Date on whose behalf they make the registration and (ii) as per shareholder, for which number of shares registration for the meeting is requested. At the moment of registration, the Intermediaries are requested to state the complete address details of the shareholders in order to efficiently verify shareholding.

ABN AMRO shall provide the shareholders who have duly registered with an admission card directly or via their Intermediary. Such admission card is to be presented at the registration desk at the meeting. The registration desk shall be open from 12.30 hours until 13.00 hours CEST. It is not possible to register after this time. Attendees may be asked to produce proof of identity and may be denied access in case of inability to prove identity.

Voting by proxy and voting prior to the meeting

Shareholders who do not wish to attend the meeting in person, may grant a proxy including voting instructions to ABN AMRO authorising such person to attend the meeting on their behalf. In order to vote by proxy, shareholders must have registered their shares in the manner as described above. Shareholders can submit their proxy and voting instructions online via www.abnamro.com/evoting or by e-mail via corporate.broking@nl.abnamro.com or Corporate Broking (HQ7050), not later than on Thursday 14 June 2018 17.30h CEST.

A proxy form can be found here www.curetis.com/en/investors/share-information/annual-general-meeting.html. A paper version of the proxy form can be obtained free of charge at the offices of:

- (a) ABN AMRO Bank N.V. at Gustav Mahlerlaan 10, 1082 PP Amsterdam, the Netherlands, or by e-mail via corporate.broking@nl.abnamro.com; or
- (b) Curetis N.V. at Max-Eyth-Straße 42, 71088 Holzgerlingen, Germany, or by e-mail via ir@curetis.com

Alternatively, shareholders who do not wish to attend the meeting in person may also cast their votes electronically prior to the meeting. In order to vote electronically prior to the meeting, shareholders must have registered their shares in the manner as described above. Shareholders can vote online via www.abnamro.com/evoting not later than on Thursday 14 June 2018 17.30h CEST.

Questions in respect of agenda items

As from the date of this notice and not later than on Thursday 14 June 2018 17.30h CEST, shareholders may submit written questions in respect of the agenda items by e-mail via ir@curetis.com. These questions shall, where appropriate and as much as possible in combined form, be discussed at the meeting.

Holzgerlingen, Germany, 9 May 2018

Curetis N.V.

The Management Board

**EXPLANATORY NOTES TO THE AGENDA
ANNUAL GENERAL MEETING 2018 CURETIS N.V.**

Agenda item 2: the presentation of the management report 2017 (discussion item)

The Management Board will give a presentation on the performance of Curetis N.V. (the "Company") in 2017 as described in the management report 2017. Subsequently, the shareholders will be invited to discuss the management report 2017.

Agenda item 3: the implementation of the new Dutch Corporate Governance Code within the Company (discussion item)

The Management Board will give a short presentation on the implementation of the new Dutch Corporate Governance Code within the Company.

In line with the new Dutch Corporate Governance Code, the Supervisory Board added to the Supervisory Board profile that at least one Supervisory Director shall have specific expertise in the field of technological innovation and new business models. No other material changes to the Supervisory Board profile were made.

Agenda item 4: the explanation of the Management Board remuneration policy (discussion item)

Pursuant to section 2:135 subsection 5a of the Dutch Civil Code ("DCC"), this agenda item aims to discuss the implementation of the Management Board remuneration policy in 2017.

The discussion shall take place on the basis of the relevant information as referred to in section 2:383c up to and including 2:383e DCC. This information is included in the remuneration report and in the explanatory notes to the annual accounts. The Management Board remuneration policy and the remuneration report are published on www.curetis.com. Reference is also made to pages 62 up to and including 67 of the management report 2017.

Agenda item 5: the adoption of the annual accounts 2017 and the allocation of the result (voting item)

On 30 April 2018, each Managing Director and each Supervisory Director signed the annual accounts 2017, as drawn up by the Management Board. The annual accounts 2017 were published on 30 April 2018 and are now submitted for adoption by the General Meeting.

Agenda item 6: the explanation on the company's reserves and dividend policy (discussion item)

Reference is made to pages 72 and 73 of the management report 2017.

Agenda item 7: discharge of the Managing Directors for their management during the financial year 2017 (voting item)

It is proposed to grant a discharge from liabilities to each of the Managing Directors for the performance of their duties as Managing Director of the Company during the financial year 2017, insofar as the performance of such duties is disclosed in the annual accounts 2017 and the management report 2017 or has otherwise been communicated to the General Meeting.

Agenda item 8: discharge of the Supervisory Directors for their supervision during the financial year 2017 (voting item)

It is proposed to grant a discharge from liabilities to each of the Supervisory Directors for the performance of their duties as Supervisory Director of the Company during the financial year 2017, insofar as the performance of such duties is disclosed in the annual accounts 2017 and the management report 2017 or has otherwise been communicated to the General Meeting.

Agenda item 9: the appointment of Managing Directors (voting item)

Oliver Schacht and Achim Plum were appointed as Managing Directors as per 10 November 2015. Their terms expire as per 31 December 2018. Oliver Schacht and Achim Plum are eligible for reappointment.

The Supervisory Board makes a nomination and proposal to the General Meeting, in accordance with article 17.1 of the articles of association of the Company:

- (a) to reappoint Oliver Schacht as Managing Director of the Company for a term as per 1 January 2019 and expiring as per 31 December 2021;
- (b) to reappoint Achim Plum as Managing Director of the Company for a term as per 1 January 2019 and expiring as per 31 December 2021;
- (c) to appoint Christopher Bernard as Managing Director of the Company for a term as per the end of the Annual General Meeting 2018 and expiring by the end of the Annual General Meeting of the Company to be held in the year 2021.

Each appointment shall be voted for separately.

Information on the nominated Managing Directors:

(a) Oliver Schacht, Ph.D.:

Mr. Oliver Schacht, a corporate finance professional and expert in the molecular diagnostics industry, has been CEO of Curetis since April 2011 and prior to that was a Supervisory Board Member of Curetis AG from mid-2010 to end of the first quarter of 2011. He was a co-founder and the CFO of Epigenomics AG in Berlin and the CEO of the U.S. subsidiary Epigenomics Inc. (Seattle, USA). Mr. Schacht has extensive experience in developing and implementing commercial strategies and financing measures (including two IPOs), as well as in corporate finance, M&A transactions and alliance negotiations. During his time at Epigenomics AG (1999-2011), he headed all central business functions, including corporate finance, investor relations, PR, marketing and business development at the Berlin headquarters. Mr. Schacht also serves on the Board of BIO Deutschland e.V. as treasurer and on the Supervisory Board of Protagen AG (Dortmund, Germany). Mr. Schacht obtained his Diploma in European Business Administration at the European School of Business in Reutlingen and London in 1994 as well as a Master's degree and a Ph.D. at the University of Cambridge (UK). During his time at Mercer Management Consulting (now Oliver Wyman) from 1995 to 1999, he worked on projects in M&A, growth strategies and re-organization in the pharmaceutical, biotechnology and other industries. He has co-founded several start-up companies in biotech, IT and education in Europe and the USA.

(b) Dr. Achim Plum:

Dr. Achim Plum joined Curetis in 2015 as Chief Commercial Officer and has held the position of Chief Business Officer since summer 2017. Dr. Plum oversees all corporate business development, portfolio management and company strategy efforts, and is one of the Managing Directors of Ares Genetics GmbH. Dr. Plum also serves as Managing Director in all of Curetis' international commercial subsidiaries. As of 2018, Dr. Plum also directly manages Curetis' corporate communications (PR&IR), legal and HR.

Dr. Plum joined from a senior management position with Siemens, where he was at last heading global Diagnostics and Bioscience Research in the Siemens Healthcare Technology Center. Prior to Siemens, Dr. Plum worked for eight years with the publicly traded German-American molecular diagnostics company Epigenomics AG, most recently as Senior Vice President Business and Strategy. At Epigenomics, he built sales and marketing teams and distribution networks in Europe and the U.S., negotiated strategic commercial agreements with leading diagnostics industry players and led Epigenomics' corporate communications and compliance functions. Following undergraduate studies at the University of Bonn (Germany) and the University of East Anglia in Norwich (UK), Dr. Plum obtained his doctorate in Molecular Genetics from the University of Bonn in 1999 for developing and studying novel genetic models of human diseases.

(c) Christopher Bernard:

Christopher Bernard currently is President & CEO of Curetis USA, Inc. and EVP Global Sales. He has more than 22 years of experience in the diagnostics and biopharmaceutical industry as well as in the translational research, including roles in senior executive management, strategic development, product commercialization, marketing and sales. Prior to joining Curetis, Chris had been the Chief Commercial Officer at Epic Sciences and responsible for the expansion of Epic's technology. Prior to Epic Sciences, he was Senior Vice President, Sales and Marketing and an officer at Metabolon Inc and Vice President and Officer at Abaxis Inc. At Abaxis he had been responsible for sales and marketing of the point-of-care diagnostics platform Piccolo Xpress®. He began his career at Cytoc Corporation (Hologic Inc.) where he was regional business director responsible for growth in sales and management of a portfolio of diagnostic products, including the ThinPrep® Pap Test and Imager and NovaSure® endometrial ablation. Chris Bernard holds a BA in psychobiology from Hiram College, Ohio, USA where he also sits on the board of the entrepreneurial leadership program.

Agenda item 10: authorisation of Supervisory Board to grant stock options to Managing Directors (voting item)

The Supervisory Board makes a proposal to the General Meeting, in accordance with article 18.3 of the Articles of Association of the Company and clause 5.1 of the Stock Option Plan as established in the General Meeting on 16 June 2016 (the "**Stock Option Plan**"), to authorize the Supervisory Board to grant to Mr. O. Schacht up to 60,000 and Dr. Achim Plum up to 40,000 stock options stock options effective per 1 January 2019.

Such stock options would be granted as part of their new service contract as managing directors of the Company and are subject to the following performance target: "Subject to the condition that Curetis has raised and has unconditionally at its disposal a total amount of € 20,000,000 of additional capital (equity and/or debt) ultimately per 31 December 2018 and at the sole discretion of the Supervisory Board...".

Agenda item 11: amendment of the Management Board remuneration policy (voting item)

Reference is made to the draft Management Board remuneration policy. Amendments were made necessary by results of a systematic benchmarking exercise of executive compensation in the molecular diagnostics industry with comparable European and US players as well as other small cap European life science companies that are listed on Euronext or other relevant European exchanges and the subsequent discussion in the Remuneration Committee and the negotiations between Oliver Schacht, Dr. Achim Plum and the Supervisory Board on their new contracts as Managing Directors and because of the new Dutch Corporate Governance Code.

Agenda item 12: the appointment of Supervisory Directors (voting item)

Dr. Rudy Dekeyser was reappointed Supervisory Director as per 23 June 2017. Dr. Werner Schäfer was appointed as Supervisory Director as per 10 November 2015. Their terms expire as per the end of the Annual General Meeting 2018. Dr. Rudy Dekeyser and Dr. Werner Schäfer are eligible for reappointment.

The Supervisory Board makes a nomination and proposal to the General Meeting, in accordance with article 24.3 of the articles of association of the Company:

- (a) to reappoint Dr. Rudy Dekeyser for a term as per the end of the Annual General Meeting 2018 and expiring by the end of the Annual General Meeting of the Company to be held in the year 2019;
- (b) to reappoint Dr. Werner Schäfer for a term as per the end of the Annual General Meeting 2018 and expiring by the end of the Annual General Meeting of the Company to be held in the year 2020;

According to Best Practice Provision 2.1.8 of the new Dutch Corporate Governance Code Dr. Werner Schäfer is independent, whilst Dr. Rudy Dekeyser is not, since he is affiliated with LSP Curetis Pooling

B.V., which is a major shareholder of the Company (holding more than 10% of the issued and outstanding share capital).

Each appointment shall be voted for separately.

Information on the nominated Supervisory Directors:

- (a) Dr. Rudy Dekeyser (born on 26 December 1961 in Oostende, Belgium, citizenship: Belgian) is a Supervisory Director of the Company. Dr. Dekeyser joined LSP in 2012 and is Managing Partner of LSP's Health Economics Funds and invests in medical device, diagnostic and digital health companies. Prior to joining LSP, Dr. Dekeyser was a co-founder of VIB in 1995 and Managing Director of the research institute for 17 years. At VIB, he was also responsible for the management of a large patent estate, the licensing activities and the establishment of start-ups such as Devgen (acquired by Syngenta), CropDesign (acquired by BASF), Ablynx (listed on Euronext and Nasdaq and recently acquired by Sanofi), Actogenix (acquired by Intrexon) and Multiplicom (acquired by Agilent). Rudy was a catalyst in the development of a life sciences cluster in Flanders by uniting the actors in the life sciences association FlandersBio, building bio-incubators and triggering the establishment of bio-accelerators. He has been a chairman and non-executive director on many company boards and is currently a board member at Sequana Medical, reMYND and Celyad. He is chairman of EMBLEM (EMBL's business arm) and is a member of the supervisory/advisory board of several not-for-profit foundations which are funding life sciences research for the benefit of society. Since November 2014, he has been a member of the supervisory board at Curetis. Dr. Dekeyser holds a Ph.D. in Molecular Biology from Ghent University.

The reasons for the proposed reappointment are, to keep his comprehensive knowledge available to Curetis and ensure continuity in the Supervisory Board.

He holds no shares in the share capital of the Company;

- (b) Dr. Werner Schäfer was born on 16 January 1948 in Arolson, Germany. His citizenship is German.

Dr. Werner Schaefer has been elected Vice Chairman of the Supervisory Board upon the IPO. He is a specialist in the in-vitro diagnostics industry and he has nearly 30 years of management experience in this area, having held various international leadership positions throughout his career – including general management, marketing and R&D at major companies such as Behringwerke/Hoechst, Abbott, Boehringer Mannheim and Roche Diagnostics. At Boehringer and Roche, he led the laboratory systems business unit and he served as a member of the Executive Board of Roche Diagnostics GmbH until 2001. Since then, he has worked as a consultant and serves on various executive boards and supervisory boards in highly specialized diagnostics and medical technology companies. He was a member of the Supervisory Board of BRAHMS AG (2002 to 2009, sold to (Thermo Fisher) mtm laboratories AG (2003 to 2011, sold to Roche), Vivacta Limited (2006 to 2012, sold to Novartis), Signature AG (2012 to 2013), Genomatix Software GmbH (2011 to 2013) and Cognoptix Inc. (2009 to 2014). He currently serves as a member of the Advisory Board of Human GmbH (since 2005), as the Chairman of the Board of Directors of ProteoMediX AG (since 2012) and as Vice-Chairman of Curetis (previously Curetis AG - since 2014). Dr. Schaefer holds a Ph.D. in Chemistry from Philipps University Marburg.

The reasons for the proposed reappointment are, to keep his comprehensive knowledge available to Curetis and ensure continuity in the Supervisory Board.

He holds 2,702 shares in the share capital of the Company;

Agenda item 13: approval of granting stock options to Supervisory Directors (voting item)

The Management Board and the Supervisory Board make a proposal to the General Meeting to approve the granting of a maximum of 10,000 stock options to each Supervisory Director on 1 July 2018 in accordance with the Stock Option Plan and in accordance with the terms included in the remuneration

of the Supervisory Directors as adopted by the General Meeting on 16 June 2016. A copy of the remuneration of the Supervisory Directors can be found on www.curetis.com.

Agenda item 14: appointment of the auditor for the financial year 2018 (voting item)

The Supervisory Board makes a proposal to the General Meeting, in accordance with article 10.2 under (k) of the Supervisory Board Rules of the Company, to reappoint PwC as external auditor for the audit of the annual accounts for the financial year 2018.

Agenda item 15: the extension of the designation of the Management Board to issue new shares and rights to subscribe for shares (voting item)

The Management Board makes a proposal to the General Meeting, in accordance with articles 6.1 and 6.4 of the articles of association of the Company, to designate the Management Board as the company body authorised to issue ordinary shares in the share capital of the Company and to grant rights to subscribe for ordinary shares in the share capital of the Company (such future shares and such future options together: the "Future Securities"), subject to the approval of the Supervisory Board, for a period of 18 months after the date of the Annual General Meeting 2018, with due observance of the following restrictions:

- (a) the Management Board may only resolve to issue or grant Future Securities up to a maximum of 10% of the total number of ordinary shares issued on the date of the Annual General Meeting 2018 (the "AGM 2018 Date"); and
- (b) the Management Board may resolve to issue or grant Future Securities in addition to the Future Securities as referred to above sub (a), up to maximum of (another) 10% of the total number of ordinary shares issued on the AGM 2018 Date, if and to the extent such additional Future Securities are used to in relation to mergers and acquisitions or strategic alliances involving any or more of the Company and its group companies as a party; and
- (c) the Management Board may resolve to issue or grant Future Securities in addition to the Future Securities as referred to above sub (a) and (b), up to maximum of 1,639,257 Future Securities, if and to the extent such additional Future Securities are used for the implementation of the Stock Option Plan.

The Supervisory Board has approved this proposal of the Management Board in accordance with articles 6.1 and 6.4 of the articles of association of the Company.

The designation as referred to sub (a) and (b) are in line with standing practice of the Company and market practices in the Netherlands. The designation as referred to sub (c) is intended to give the Management Board the mandate to implement the Stock Option Plan, subject to the approval of the Supervisory Board. 1,639,257 is 10% of the number of ordinary shares issued at the date of the notice for the AGM.

Agenda item 16: the extension of the designation of the Management Board to limit or exclude pre-emption rights on newly issued shares or rights to subscribe for shares (voting item)

The Management Board makes a proposal to the General Meeting, in accordance with articles 7.3 and 7.6 of the articles of association of the Company, to designate the Management Board as the company body authorised to limit or exclude the pre-emption rights in respect of issues or grants of Future Securities made by making use of the designation of the Management Board as referred to in agenda item 15, subject to the approval of the Supervisory Board, for a period of 18 months after the AGM 2018 Date.

The Supervisory Board has approved the proposal of the Management Board in accordance with articles 7.3 and 7.6 of the articles of association of the Company.

This authorisation is in line with standing practice of the Company and market practices in the Netherlands and may be used immediately upon taking effect.

Agenda item 17: the extension of the authorisation of the Management Board to repurchase shares (voting item)

The Management Board makes a proposal to the General Meeting to authorise the Management Board, subject to the approval of the Supervisory Board of the Company, to repurchase ordinary shares in the share capital of the Company, for a period of 18 months after the date of the AGM 2018 Date, with due observance of the following restrictions:

- (a) the Management Board may only resolve to repurchase:
 - (i) ordinary shares in the share capital of the Company up to a maximum of 10% of the total number of ordinary shares issued on the AGM 2018 Date; and
 - (ii) in addition to the shares as referred to above sub (i): (any or all of) the ordinary shares issued pursuant to the exercise of the Roll-Over Options which were granted at the occasion of the IPO of the Company;
- (b) any repurchase under such authorisation shall take place (be it on a stock exchange or in a different manner) against a price per share, excluding expenses, not lower than the nominal value of the ordinary shares and not higher than the opening price of the ordinary shares on Euronext in Amsterdam and Euronext in Brussels on the day of the repurchase increased by 10%.

The authorisations as referred to sub (i) and (ii) are in line with standing practice of the Company and market practices in the Netherlands and may be used immediately upon taking effect.

Agenda item 18: the designation of the Management Board as the company body authorised to issue new shares or grant rights to subscribe for shares in relation to strategic capital raising(s) (voting item)

In addition to the authorisations referred to under agenda item 15, the Management Board makes a proposal to the General Meeting, in accordance with articles 6.1 and 6.4 of the articles of association of the Company, to designate the Management Board as the company body authorised to issue or grant, subject to the approval of the Supervisory Board, Future Securities with a view to raise additional capital to support the execution of the Company's strategy and the development of its business, e.g. to maintain and expand its US and European commercial organisations, continue and expand its research & development pipeline for Unyvero A50 and A30 *RQ* systems and respective Application Cartridges and required clinical trials and regulatory filings, as well as the Ares Genetics research and development activities, fund the placement of Unyvero systems and general corporate purposes, with due observance of the following restrictions:

- (a) the authority granted by virtue of the resolution under this agenda item is limited up to 50% of the total number of ordinary shares issued on the AGM 2018 Date; and
- (b) the authority granted by virtue of the resolution under this agenda item shall be valid for a period of 18 months after the AGM 2018 Date.

The Supervisory Board has approved this proposal of the Management Board in accordance with articles 6.1 and 6.4 of the articles of association of the Company.

Agenda item 19: the designation of the Management Board as the company body authorised to limit or exclude pre-emption rights on newly issued shares or rights to subscribe for shares in relation to strategic capital raising(s) (voting item)

The Management Board makes a proposal to the General Meeting, in accordance with articles 7.3 and 7.6 of the articles of association of the Company, to designate the Management Board as the company body authorised to limit or exclude, subject to the approval of the Supervisory Board, the pre-emption rights in respect of the issuance or granting of Future Securities made by making use of the authorisation of the Management Board as referred to in agenda item 18, for a period of 18 months after the AGM 2018 Date.

The Supervisory Board has approved the proposal of the Management Board in accordance with articles 7.3 and 7.6 of the articles of association of the Company.

Reference is made to the explanation of the strategic capital raising(s) under agenda item 18. The authorisations granted under item 18 and 19 may be used immediately upon taking effect.

Agenda item 20: the amendment of the articles of association of Curetis N.V. (voting item)

The Management Board makes a proposal to the General Meeting, in accordance with article 38.1 of the articles of association of the Company, to resolve:

- (a) to amend the articles of association of the Company in accordance with the draft of the deed of amendment of articles of association drawn up by CMS Derks Star Busmann N.V.; and
- (b) to grant authorisation to each civil law notary, candidate civil law notary and notarial assistant working with CMS Derks Star Busmann N.V. to have the deed of amendment of articles of association executed and to perform all other legal acts which the authorised person deems necessary in connection therewith.

The amendment concerns a minor technical aspect in relation to the new Dutch Corporate Governance Code. Reference is made to the draft deed of amendment of articles of association (annex).

The Supervisory Board has approved the proposal of the Management Board in accordance with article 38.1 of the articles of association of the Company.

Holzgerlingen, Germany, 9 May 2018

Curetis N.V.

The Management Board